Anugerah 88 Logo
$1.96+0.01|(+0.51%)

Analyst Recommendation Trends

Wall Street analyst consensus for SER over the last few months:

2026-09-01
Buy: 3
S.Buy: 2
Hold: 1
Sell: 0
2026-08-01
Buy: 3
S.Buy: 2
Hold: 1
Sell: 0
2026-07-01
Buy: 3
S.Buy: 1
Hold: 1
Sell: 0
2026-06-01
Buy: 3
S.Buy: 1
Hold: 1
Sell: 0

Latest SER News

Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress"

Serina Therapeutics, Inc. Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress" Featuring Serina Therapeutics’ CEO - Thursday, September 24, 2026 10M people in the world currently living with Parkinson’s disease with no major clinical advances in 50+ yearsMeet with Serina’s CEO Steven LedgerRegister at AdvancingParkinsonsDisease.TribePublic.com HUNTSVILLE, AL, Sept. 23, 202

Yahoo9/23/2026

Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

HUNTSVILLE, AL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology enabling drug product candidates to treat neurological diseases and other indications, today announced that Steve Ledger, Chief Executive Officer, will present at the upcoming H.C. Wainwright 28th Annual Global Investment Conference. The Company will also attend o

Yahoo9/10/2026

BTIG Reiterates Buy on Serina Therapeutics, Maintains $8 Price Target

BTIG analyst Thomas Shrader reiterates Serina Therapeutics (AMEX:SER) with a Buy and maintains $8 price target.

Benzinga9/10/2026

Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2

- Independent Safety Monitoring Committee recommends advancement to Cohort 2 following blinded review of Cohort 1 safety and tolerability data – - Pharmacokinetic observations at the lowest dose evaluated were consistent with the sustained apomorphine exposure SER-252 is designed to provide – - Blinded Cohort 1 observations included sustained periods of improvement in motor function in individual patients on exploratory clinical measures – - Serina expects to report topline data from the single-

Yahoo9/9/2026

Serina Therapeutics Receives Recommendation From Independent Safety Monitoring Committee To Continue Its Phase 1b Registrational Trial Of SER-252 To Cohort 2

Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced

Benzinga9/9/2026

Related Stocks (Peers)

Companies operating in similar sectors to SER:

CELUTXTMELTXANVSSERDWTXTILCRVOTVGN950160.KQ

Recent Insider Transactions

DateNameShares ChangedPriceValue
2026-07-22Simon Farrell+30,500--
2026-07-07Brannan Stephen K.+1,000$2.03$2,030
2026-06-17Marshall Richard Peter+15,250--
2026-06-17Brannan Stephen K.+15,250--
2026-06-17Venkatesan Jay-96,525$2.25$217,181
2026-06-17Venkatesan Jay+15,250--
2026-06-17Venkatesan Jay+224,152$2.25$504,342
2026-06-17Bailey Gregory-762,548$2.25$1,715,733
2026-06-17Bailey Gregory+3,333,333--
2026-06-17Bailey Gregory+15,250--
2026-06-17Bailey Gregory+6,666,667$2.2499$14,999,334
2026-06-17Bailey Gregory+1,770,805$2.25$3,984,311
2026-06-17WILSON KAREN J+15,250--
2026-06-12WILSON KAREN J+5,000$1.77$8,850
2026-06-11WILSON KAREN J+5,100$1.745$8,900
2026-05-26LEDGER STEVEN A+10,100$1.93$19,493
2026-05-22Venkatesan Jay+589$1.78$1,048
2026-05-22WILSON KAREN J+10,000$1.93$19,300
2026-05-21Tenjarla Srini+85,558--
2026-05-21Moreadith Randall+85,558--
2026-05-21WILSON KAREN J+10,000$1.77$17,700
2026-05-21CURHAN GREGORY S+123,019--
2026-05-21LEDGER STEVEN A+380,825--
2026-05-19Marshall Richard Peter+12,183$1.65$20,102
2026-03-31Venkatesan Jay+7,553$1.94$14,653
2026-03-31Bailey Gregory+59,667$1.94$115,754
2026-03-23Moreadith Randall-6,500--
2026-03-23Moreadith Randall-6,500$2.8566$18,568
2026-03-23Moreadith Randall+6,500$0.06$390
2026-03-19Moreadith Randall-39,000--
2026-03-19Moreadith Randall-39,000$2.5$97,500
2026-03-19Moreadith Randall+39,000$0.06$2,340
2026-02-03Tenjarla Srini+69,000--
2026-02-03Moreadith Randall+69,000--
2026-02-03GILL SIMBA+92,000--
2026-02-03LEDGER STEVEN A+230,100--
2026-02-02Moreadith Randall-6,500--
2026-02-02Moreadith Randall-6,500$3.0277$19,680
2026-02-02Moreadith Randall+6,500$0.06$390
2026-01-28Moreadith Randall-6,500--
2026-01-28Moreadith Randall-6,500$3.567$23,186
2026-01-28Moreadith Randall+6,500$0.06$390
2026-01-22Moreadith Randall-2,500--
2026-01-22Moreadith Randall-2,500$2.95$7,375
2026-01-22Moreadith Randall+2,500$0.06$150
2026-01-21Moreadith Randall-2,000--
2026-01-21Moreadith Randall-2,000$3$6,000
2026-01-21Moreadith Randall+2,000$0.06$120
2026-01-20Moreadith Randall-2,000--
2026-01-20Moreadith Randall-2,000$3.07$6,140
2026-01-20Moreadith Randall+2,000$0.06$120
2026-01-14Moreadith Randall-1,084--
2026-01-14Moreadith Randall-1,084$2.5031$2,713
2026-01-14Moreadith Randall+1,084$0.06$65
2026-01-13Moreadith Randall-5,416--
2026-01-13Moreadith Randall-5,416$2.5$13,540
2026-01-13Moreadith Randall+5,416$0.06$325
2026-01-08Moreadith Randall-13,000--
2026-01-08Moreadith Randall-13,000$2.6887$34,953
2026-01-08Moreadith Randall+13,000$0.06$780
2025-12-23Moreadith Randall-4,100--
2025-12-23Moreadith Randall-4,100$2.6$10,660
2025-12-23Moreadith Randall+4,100$0.06$246
2025-12-22Moreadith Randall-5,673--
2025-12-22Moreadith Randall-5,673$2.6737$15,168
2025-12-22Moreadith Randall+5,673$0.06$340
2025-12-16Moreadith Randall-3,227--
2025-12-16Moreadith Randall-3,227$2.9631$9,562
2025-12-16Moreadith Randall+3,227$0.06$194
2025-12-12Moreadith Randall-1,700--
2025-12-12Moreadith Randall-1,700$3.2597$5,541
2025-12-12Moreadith Randall+1,700$0.06$102
2025-12-11Moreadith Randall-3,555--
2025-12-11Moreadith Randall-3,555$3.2404$11,520
2025-12-11Moreadith Randall+3,555$0.06$213
2025-12-10Moreadith Randall-645--
2025-12-10Moreadith Randall-645$3.35$2,161
2025-12-10Moreadith Randall+645$0.06$39
2025-12-09Moreadith Randall-600--
2025-12-09Moreadith Randall-600$3.3133$1,988
2025-12-09Moreadith Randall+600$0.06$36
2025-12-03Moreadith Randall-5,000--
2025-12-03Moreadith Randall-5,000$3.5246$17,623
2025-12-03Moreadith Randall+5,000$0.06$300
2025-12-02Moreadith Randall-1,500--
2025-12-02Moreadith Randall-1,500$3.9052$5,858
2025-12-02Moreadith Randall+1,500$0.06$90
2025-11-25Moreadith Randall-5,965--
2025-11-25Moreadith Randall-5,965$3.9001$23,264
2025-11-25Moreadith Randall+5,965$0.06$358
2025-11-24Moreadith Randall-535--
2025-11-24Moreadith Randall-535$3.935$2,105
2025-11-24Moreadith Randall+535$0.06$32
2025-11-18Moreadith Randall-6,500--
2025-11-18Moreadith Randall-6,500$3.7541$24,402
2025-11-18Moreadith Randall+6,500$0.06$390
2025-11-10Moreadith Randall-6,500--
2025-11-10Moreadith Randall-6,500$4.1$26,650
2025-11-10Moreadith Randall+6,500$0.06$390
2025-11-07Marshall Richard Peter+10,000--
2025-11-07Brannan Stephen K.+10,000--
2025-11-07Venkatesan Jay+10,000--
2025-11-07Bailey Gregory+10,000--
2025-11-07WILSON KAREN J+10,000--
2025-11-05Moreadith Randall-3,398--
2025-11-05Moreadith Randall-3,398$4.24$14,408
2025-11-05Moreadith Randall+3,398$0.06$204
2025-11-04Moreadith Randall-3,102--
2025-11-04Moreadith Randall-3,102$4.3953$13,634
2025-11-04Moreadith Randall+3,102$0.06$186
2025-10-28Moreadith Randall-5,551--
2025-10-28Moreadith Randall-5,551$4.9615$27,541
2025-10-28Moreadith Randall+5,551$0.06$333
2025-10-27Moreadith Randall-949--
2025-10-27Moreadith Randall-949$5.1857$4,921
2025-10-27Moreadith Randall+949$0.06$57
2025-10-20Moreadith Randall-6,500--
2025-10-20Moreadith Randall-6,500$4.9672$32,287
2025-10-20Moreadith Randall+6,500$0.06$390
2025-10-13Moreadith Randall-4,326--
2025-10-13Moreadith Randall-4,326$5.2$22,495
2025-10-13Moreadith Randall+4,326$0.06$260